Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupIndolent LymphomasDiseaseNHL, T-Cell Type, Cutaneous, UnspecifiedSubgroupICD10C84.8MeSHLymphoma, T-Cell, CutaneousSequenceChemotherapyChemo-substanceBortezomibChemo-substanceBortezomibChemo-substanceBortezomibChemo-substanceBortezomibNo. Substances1 RadiotherapySupportive therapySupportive substanceAciclovirGranisetronSupportive substanceAciclovirGranisetronSupportive substanceAciclovirGranisetronSupportive substanceAciclovirGranisetronNo. Substances2Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationSecond lineTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlEmetogenicity (MASCC/ESMO)NeurotoxicityNeutropeniaThrombocytopenia below 50 000/µl only studiesPublicationAuthorZinzani PLDiseaseKutanes T-Zell-Lymphom, vortherapiert, ECOG 0-1OriginUniversity of Bologna, Bologna, ItalyProtocols in Revision 1 protocol foundProtocols under revision.Bortezomib 1.3, Cutaneous T-cell Lymphoma (PID2459 V1.0)
